Mentioned in

References in periodicals archive

Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged s65 years: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Increasing Pneumococcal Vaccinations in Older Adults

On September 19, 2014, CDC published a recommendation of the Advisory Committee on Immunization Practices (ACIP) for routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged [greater than or equal to] 65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23).

Pneumococcal vaccination among Medicare beneficiaries occurring after the advisory committee on immunization practices recommendation for routine use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults aged [greater than or equal to] 65 Years

Pneumococcal polysaccharide vaccine (PPV): vaccine coverage estimates [cited 2016 Jul 19].

Increased invasive pneumococcal disease, North East England, UK

[2] Centers for Disease Control and Prevention (CDC) and Advisory Committee on Immunization Practices, "Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)," Morbidity and Mortality Weekly Report, vol.

Survey of obstetrics and gynecology residents regarding pneumococcal vaccination in pregnancy: education, knowledge, and barriers to vaccination

Many people with HIV got a pneumococcal vaccine called PPSV23 (for 23-valent pneumococcal polysaccharide vaccine), which has been available since 1983.

Newer pneumococcal vaccine rouses immune response in adults with HIV

The 23-valent pneumococcal polysaccharide vaccine (PPSV-23) contains up to 98% of the pneumococcal serotypes that cause pneumonia.

Effects of Immunosuppressants on Immune Response to Vaccine in Inflammatory Bowel Disease

The new adult vaccination recommendations from the Advisory Committee on Immunization Practices, which were published in the February issue of Annals of Internal Medicine, encourage adults ages 65 and older to receive a dose of pneumococcal conjugate vaccine, or PCV13, first, followed by a dose of pneumococcal polysaccharide vaccine, or PPSV23, six to 12 months later.

Pneumonia vaccine guidelines updated

* the addition of the 13-valent pneumococcal conjugate vaccine (PCV13) to the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in the routine older-adult recommendations; (3)

Immunization update: what's changed, what's on the way

The one that protects adults against 23 strains of streptococcus pneumonia bacteria is called pneumococcal polysaccharide vaccine (PPSV23), and it is marketed under the brand name Pneumovax.

Vaccination campaign to combat pneumonia from Sunday

Experts recommend that adults 65 and older receive the pneumococcal polysaccharide vaccine to help prevent meningitis.

Bacterial meningitis in seniors

Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. MMWR Recomm Rep 2010; 59:1-18.

VACCINE PREVENTABLE DISEASES IN THE XXI CENTURY